Some historical highlights
1992 – IPOPI is created
1996 – First staff member is hired and publication of a quarterly newsletter
2003 – Immunoglobulins are removed from the World Health Organization (WHO) List of Essential Medicines (EML).
2004 – IPOPI first high-level EU meeting at European Parliament’s Scientific and Technological Assessment Options Committee (STOA)
2005 – David Watters becomes IPOPI Executive Director.
2006 – IPOPI’s European PID Consensus Conference in 2006 in Langen, Germany).
2007 – Immunoglobulins are reinstated in the World Health Organization (WHO) List of Essential Medicines (EML) following IPOPI/ International Union of Immunological Societies (IUIS) joint campaign in collaboration with key stakeholders.
2007 – IPOPI is accepted as a member of the WHO Global Collaboration on Blood Safety.
2010 – IPOPI expands its staff. Johan Prevot joins as Director of Development, succeeding to David Watters in the following year as Executive Director.
2011 – First IPOPI EU PID Forum is held. SCID newborn screening is discussed at the European Parliament.
2011 – IPOPI reaches 30 national member organisations.
2012 – Asian development plan is created thank to a generous grant from one of IPOPI’s founders, Bob LeBien.
2013 – First International Primary Immunodeficiencies Congress – IPIC – is held in Estoril, Portugal
2014 – Publication of the Principles of Care for Primary Immunodeficiencies paper on Frontiers of Immunology
2015 – IPIC2015 takes place in Budapest, Hungary, with 700 participants.
2016 – IPOPI reaches 60 National Member Organisations.
In the pipeline:
IPIC2017 in Dubai
IPOPI XV Biennial Meeting in Lisbon in 2018
Several PID awareness and advocacy campaigns in various regions of the world.